BACKGROUND: Epithelial mesenchymal transition (EMT) of postoperative remnants of lens epithelial cells (LECs) can lead to posterior capsule opacification. This study was designed to determine the effect of signaling pathways that contribute to TGF-beta2-mediated EMT in human lens epithelial B-3 cells (HLEB-3 cells). METHODS: The HLEB-3 cells were cultured and stimulated with TGF-beta2 at different concentrations for an indicated time. The effect of TGF-beta2 on cell cycle distribution was measured by flow cytometry. Western blot and immunofluorescence were used to analyze changes in connexin 43, fibronectin, desmin and integrin beta(1) protein expression associated with EMT in HLEB-3 cells. Activation of phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways was also detected by Western blot. RESULTS: The cell cycle progression of HLEB-3 cells was limited, and the cells underwent morphological alteration after treatment with TGF-beta2. Stimulation of HLEB-3 cells with TGF-beta(2) suppressed connexin 43 protein expression, increased fibronectin, desmin and integrin beta1 protein expression. TGF-beta2 activated PI3K/Akt in a time-dependent manner, but not extracellular signal-regulated kinase and p38 MAPK. The activation of PI3K/Akt was necessary for the TGF-beta(2)-stimulated downregulation of connexin 43, which in turn was necessary for TGF-beta2-induced EMT in HLEB-3 cells. CONCLUSIONS: TGF-beta(2) is a potent growth factor for LEC EMT. TGF-beta(2)-induced EMT in LECs is mediated by the downregulation of connexin 43, which is regulated through the PI3K/Akt pathway. (c) 2008 S. Karger AG, Basel
BACKGROUND: Epithelial mesenchymal transition (EMT) of postoperative remnants of lens epithelial cells (LECs) can lead to posterior capsule opacification. This study was designed to determine the effect of signaling pathways that contribute to TGF-beta2-mediated EMT in human lens epithelial B-3 cells (HLEB-3 cells). METHODS: The HLEB-3 cells were cultured and stimulated with TGF-beta2 at different concentrations for an indicated time. The effect of TGF-beta2 on cell cycle distribution was measured by flow cytometry. Western blot and immunofluorescence were used to analyze changes in connexin 43, fibronectin, desmin and integrin beta(1) protein expression associated with EMT in HLEB-3 cells. Activation of phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways was also detected by Western blot. RESULTS: The cell cycle progression of HLEB-3 cells was limited, and the cells underwent morphological alteration after treatment with TGF-beta2. Stimulation of HLEB-3 cells with TGF-beta(2) suppressed connexin 43 protein expression, increased fibronectin, desmin and integrin beta1 protein expression. TGF-beta2 activated PI3K/Akt in a time-dependent manner, but not extracellular signal-regulated kinase and p38 MAPK. The activation of PI3K/Akt was necessary for the TGF-beta(2)-stimulated downregulation of connexin 43, which in turn was necessary for TGF-beta2-induced EMT in HLEB-3 cells. CONCLUSIONS:TGF-beta(2) is a potent growth factor for LEC EMT. TGF-beta(2)-induced EMT in LECs is mediated by the downregulation of connexin 43, which is regulated through the PI3K/Akt pathway. (c) 2008 S. Karger AG, Basel
Authors: Shyamal Dilhan Weeraratne; Vladimir Amani; Natalia Teider; Jessica Pierre-Francois; Dominic Winter; Min Jeong Kye; Soma Sengupta; Tenley Archer; Marc Remke; Alfa H C Bai; Peter Warren; Stefan M Pfister; Judith A J Steen; Scott L Pomeroy; Yoon-Jae Cho Journal: Acta Neuropathol Date: 2012-03-10 Impact factor: 17.088
Authors: A Sood; S Salih; D Roh; L Lacharme-Lora; M Parry; B Hardiman; R Keehan; R Grummer; E Winterhager; P J Gokhale; P W Andrews; C Abbott; K Forbes; M Westwood; J D Aplin; E Ingham; I Papageorgiou; M Berry; J Liu; A D Dick; R J Garland; N Williams; R Singh; A K Simon; M Lewis; J Ham; L Roger; D M Baird; L A Crompton; M A Caldwell; H Swalwell; M Birch-Machin; G Lopez-Castejon; A Randall; H Lin; M-S Suleiman; W H Evans; R Newson; C P Case Journal: Nat Nanotechnol Date: 2011-11-06 Impact factor: 39.213
Authors: Taylor R Murphy; Thomas S Vihtelic; Kristina E Ile; Corey T Watson; Gregory B Willer; Ronald G Gregg; Vytas A Bankaitis; David R Hyde Journal: Exp Eye Res Date: 2011-06-23 Impact factor: 3.467
Authors: Heather L Chandler; Terah R Webb; Curtis A Barden; Mirunalni Thangavelu; Samuel K Kulp; Ching-Shih Chen; Carmen M H Colitz Journal: Mol Vis Date: 2010-10-29 Impact factor: 2.367
Authors: R Liegl; C Wertheimer; M Kernt; D Docheva; A Kampik; K H Eibl-Lindner Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-11-22 Impact factor: 3.117